The impact of thiopurine S-methyltransferase polymorphism on azathioprine-induced myelotoxicity in renal transplant recipients

Therapeutic Drug Monitoring

Volumn 27, Issue 4, 2005, Pages 435-441

  Kurzawski, Mateusz ^a   Dziewanowski, Krzysztof ^b   Gawrońska Szklarz, Barbara ^a   Domański, Leszek ^a   Droździk, Marek ^a  

^a POMERANIAN MEDICAL UNIVERSITY   (Poland)

^b Department of General and Transplantation Surgery   (Poland)

Author keywords

Azathioprine; Genetic polymorphism; Renal transplantation; Thiopurine S methyltransferase

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN; PREDNISONE; THIOPURINE METHYLTRANSFERASE;

ADULT; ALLELE; ARTICLE; BONE MARROW TOXICITY; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME MECHANISM; ERYTHROCYTE COUNT; FEMALE; GENETIC POLYMORPHISM; GENETIC RISK; GENOTYPE; HETEROZYGOTE; HOMOZYGOTE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT; KIDNEY GRAFT REJECTION; LEUKOCYTE COUNT; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; METHYLATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SIDE EFFECT; THROMBOCYTE COUNT; WILD TYPE;

ADOLESCENT; ADULT; AGED; ALLELES; AZATHIOPRINE; BONE MARROW DISEASES; CHILD; CYCLOSPORINE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GENE FREQUENCY; GENOTYPE; GRAFT REJECTION; HEMATOLOGIC TESTS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; LEUKOPENIA; MALE; METHYLTRANSFERASES; POLYMORPHISM, GENETIC; PREDNISONE; TIME FACTORS;

EID: 23244464086     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ftd.0000164393.09402.c9     Document Type: Article

References (33)

1. Krynetski EY, Evans WE. Pharmacogenetics as a molecular basis for individualised drug therapy: the thiopurine S-methyltransferase paradigm. Pharm Res. 1999;16:342-349.
2. Krynetski EY, Evans WE. Genetic polymorphism of thiopurine S-methyltransferase: clinical importance and molecular mechanisms. Pharmacogenetics. 1996;6:279-290.
3. McLeod HL, Siva C. The thiopurine S-methyltransferase gene locus-implication for clinical pharmacogenomics. Pharmacogenomics. 2002;3:89-98.
4. Weinshilboum RM, Sladek SL. Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am J Hum Genet. 1980;32:651-662.
5. McLeod HL, Lin J-S, Scott EP, et al. Thiopurine methyltransferase activity in American white subjects and black subjects. Clin Pharmacol Ther. 1994;55:15-20.
6. Krynetski EY, Schuetz JD, Galpin AJ, et al. A single point mutation leading to loss of catalytic activity in human thiopurine S-methyltransferase. Proc Natl Acad Sci USA. 1995;92:949-953.
7. Tai HL, Krynetski EY, Yates CR, et al. Thiopurine S-methyltransferase deficiency: two nucleotide transitions define the most prevalent mutant allele associated with loss of catalytic activity in Caucasians. Am J Hum Genet. 1996;58:694-702.
8. Schaeffeler E, Fischer C, Brockmeier D, et al. Comprehensive analysis of thiopurine S-methyltransferase phenotype-genotype correlation in a large population of German-Caucasians and identification of novel TPMT variants. Pharmacogenetics. 2004;14:407-417.
9. Lennard L, Gibson BES, Nicole T, et al. Congenital thiopurine methyltransferase deficiency and 6-mercaptopurine toxicity during treatment for acute lymphoblastic leukaemia. Arch Dis Child. 1993; 69:577-579.
10. Black AJ, McLeod HL, Capell HA, et al. Thiopurine methyltransferase genotype predicts therapy-limiting severe toxicity from azathioprine. Ann Intern Med. 1998;129:716-718.
11. Relling MV, Hancock ML, Rivera GK, et al. Mercaptopurine therapy intolerance related to heterozygosity at the thiopurine methyltransferase gene locus. J Natl Cancer Inst. 1999;91:2001-2008.
12. Ishioka S, Hiyama K, Sato H, et al. Thiopurine methyltransferase genotype and the toxicity of azathioprine in Japanese. Intern Med. 1999; 38:944-947.
13. Naughton MA, Battaglia E, O'Brien S, et al. Identification of thiopurine methyltransferase (TPMT) polymorphisms cannot predict myelosuppression in systemic lupus erythematosus patients taking azathioprine. Rheumatology (Oxford). 1999;38:640-644.
14. Gearry RB, Barclay ML, Burt MJ, et al. Thiopurine S-methyltransferase (TPMT) genotype does not predict adverse drug reactions to thiopurine drugs in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2003;18:395-400.
15. McLeod HL, Coulthard S, Thomas AE, et al. Analysis of thiopurine methyltransferase variant alleles in childhood acute lymphoblastic leukaemia. Br J Haematol. 1999;105:696-700.
16. Lahiri DK, Bye S, Nurnberger JI Jr. A non-organic and non-enzymatic extraction method gives higher yields of genomic DNA from whole-blood samples that do nine other methods tested. J Biochem Biophys Metab. 1992;25:193-205.
17. Yates CR, Krynetski EY, Loennechen T, et al. Molecular diagnosis of thiopurine S-methyltransferase deficiency: genetic basis for azathioprine and mercaptopurine intolerance. Ann Intern Med. 1997;126:608-614.
18. Ameyaw MM, Collie-Duguid ES, Powrie RH, et al. Thiopurine methyltransferase alleles in British and Ghanaian populations. Hum Mol Genet. 1999;8:367-370.
19. Kurzawski M, Gawronska-Szklarz B, Drozdzik M. Frequency distribution of thiopurine S-methyltransferase alleles in a Polish population. Ther Drug Monit. 2004;26:541-545.
20. Ganiere-Monteil C, Medard Y, Lejus C, et al. Phenotype and genotype for thiopurine methyltransferase activity in French Caucasian population: impact of age. Eur J Clin Pharmacol. 2004;60:89-96.
21. Schutz E, Gummert J, Mohr F, et al. Azathioprine induced myelosuppression in thiopurine methyltransferase deficient heart transplant recipient. Lancet. 1993;341:436-437.
22. Reuther LO, Vainer B, Sonne J, et al. Thiopurine methyltransferase (TPMT) genotype distribution in azathioprine-tolerant and -intolerant patients with various disorders. The impact of TPMT genotyping in predicting toxicity. Eur J Clin Pharmacol. 2004;59:797-801.
23. Hindorf U, Peterson C, Almer S. Assessment of thiopurine methyltransferase and metabolite formation during thiopurine therapy: results from a large Swedish patient population. Ther Drug Monit. 2004;26:673-678.
24. Pandya B, Thomson W, Poulton K, et al. Azathioprine toxicity and thiopurine methyltransferase genotype in renal transplant patients. Transplant Proc. 2002;34:1642-1645.
25. Fabre MA, Jones DC, Bunce M, et al. The impact of thiopurine S-methyltransferase polymorphisms on azathioprine dose 1 year after transplantation. Transplant Int. 2004;17:531-539.
26. Evans WE, Hon YY, Bomgaars L, et al. Preponderance of thiopurine S-methyltransferase deficiency and heterozygosity among patients intolerant to mercaptopurine or azathioprine. J Clin Oncol. 2001;19:2293-2301.
27. Woodson LC, Ames MM, Selassie CD, et al. Thiopurine methyltransferase. Aromatic thiol substrates and inhibition by benzoic acid derivatives. Mol Pharmacol. 1983;4:471-478.
28. Formea CM, Myers-Huentelman H, Wu R, et al. Thiopurine S-methyltransferase genotype predicts azathioprine-induced myelotoxicity in kidney transplant recipients. Am J Transplant. 2004;4:1810-1817.
29. Pazmino PA, Sladek SL, Weinshilboum RM. Thiol S-methylation in uremia: erythrocyte enzyme activities and plasma inhibitors. Clin Pharmacol Ther. 1980;28:356-367.
30. Chocair PR, Duley JA, Simmonds HA, et al. The importance of thiopurine methyltransferase activity for the use of azathioprine in transplant recipients. Transplantation. 1992;53:1051-1056.
31. Lezaic V, Djukanovic LJ, Pavlovic-Kentera V, et al. Factors inducing posttransplant erythrocytosis. Eur J Med Res. 1997;2:407-412.
32. Clarke E, Quinn DG, McCann SR. Inhibitory effect of cyclosporin A on erythroid and stromal colonies. Eur J Haematol. 1991;47:282-286.
33. Jensen JD, Hansen HE, Pedersen EB. Increased serum erythropoietin level during azathioprine treatment in renal transplant recipients. Nephron. 1994;67:297-301.